EuroBiotech: More Articles of Note

ReViral appointed Seth Hetherington as CMO. (Pixabay)

> ViiV Healthcare teamed up with Radboud university medical center in the Netherlands to identify new early-stage HIV drug targets. Statement 

> Amryt received clearance to enroll babies and infants in its phase 3 epidermolysis bullosa trial. The expansion follows an analysis of pharmacokinetic data on patients aged four years and older enrolled in the study. Release 

> ReViral appointed Seth Hetherington as CMO. Hetherington joins ReViral from Genocea Biosciences. Statement 

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

> Compugen detailed plans to lay off 35% of its staff and consolidate its R&D activities in Israel. The cuts, which largely affect R&D, are intended to ensure Compugen has the money to reach clinical proof-of-concept readouts. Release 

> Quantum Genomics completed enrollment in a pharmacokinetic study of its modified release firibastat tablets. Statement 

> Modus Therapeutics dosed the first cohort in a phase 1 trial of its sickle cell disease drug. Release